EQRx had lim­it­ed buy­er in­ter­est, tried ac­quir­ing oth­er com­pa­nies be­fore Rev­o­lu­tion came for its cash

In No­vem­ber, EQRx pub­licly gave up on the fi­nal pieces of its low-cost med­i­cines ap­proach. But in a re­cent fi­nan­cial fil­ing, the com­pa­ny re­vealed that was the mo­ment when it al­so start­ed down the path of sell­ing it­self, a de­ci­sion that would ul­ti­mate­ly lead to it get­ting ac­quired for its cash months lat­er.

A day be­fore it an­nounced that it would ful­ly aban­don its goals as a drug price dis­rup­tor in fa­vor of “mar­ket-based pric­ing,” the com­pa­ny’s board told Gold­man Sachs to reach out to 24 bio­phar­ma com­pa­nies in the US, Eu­rope and Asia about po­ten­tial merg­ers, take-pri­vates, part­ner­ship deals or oth­er trans­ac­tions, ac­cord­ing to the se­cu­ri­ties fil­ing. Nine months lat­er, in Au­gust, EQRx said it would sell to Rev­o­lu­tion Med­i­cines in an all-stock trans­ac­tion. Share­hold­ers will vote on the pro­pos­al on Nov. 8.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER